Figure 2
Observed indisulam plasma concentrations at cycle 1 (○) and cycle 2 (•) for eight individual patients. Patients A and B received an escalated indisulam dose at cycle 2. The broken line (- - - -) represents the expected concentration time profile if capecitabine did not interact with indisulam pharmacokinetics. Patients C, D, E, F, G and H were included in the amended study and received both in cycle 1 and in cycle 2 500 mg m−2 indisulam.
